graph Evidence gap map comparisons
pembrolizumab based treatment
pembrolizumab plus SoC
mGC or mGEJC - L1 - PDL1 positive 4    
Comparator:  vs placebo plus SoC; 
Risk of bias:  low;   some concerns;   high;  NA;